到2025年底,世界最贫穷者将负担得起一种新的艾滋病毒预防药物Lenacapavir。 A new HIV prevention drug, lenacapavir, will be made affordable for the world's poorest by late 2025.

在2025年底或2026年初,新的长效艾滋病毒预防药物Lenacapavir可以到达世界上最贫穷的国家。 A new long-acting HIV prevention drug, lenacapavir, could reach the world's poorest countries by late 2025 or early 2026. 该药物已经核准用于治疗抗多种药物的艾滋病毒,在预防感染方面显示出很高的效力。 Already approved for treating multi-drug resistant HIV, the drug shows high effectiveness in preventing infection. 全球基金、 " 艾滋病紧急救援计划 " 和慈善基金会正在结成伙伴关系,以确保人们能够负担得起获得援助的机会。 The Global Fund, PEPFAR, and philanthropic foundations are partnering to ensure affordable access. Gilead Science公司与6个非专利药商签订了协议,在120个中低收入国家以较低价格生产和销售该药物,等待监管批准。 Gilead Sciences signed deals with six generic drugmakers to produce and sell the drug at lower prices in 120 low and middle-income countries, pending regulatory approvals.